3D Medicines (HKSE:01244) Operating Margin %: -31.91% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:01244 3D Medicines Inc HKSE:01244
49 GF Score
Price HK$2.02
GF Value HK$3.15
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is 3D Medicines Operating Margin %?

3D Medicines HKSE:01244 +3.33% 49 Operating Margin % is -31.91% as of Dec. 2025. GuruFocus rates HKSE:01244 with a GF Score™ of 49/100 and a GF Value™ of HK$3.15 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 943 Biotechnology companies, 3D Medicines ranks better than 62.78% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. 3D Medicines's Operating Income for the six months ended in Dec. 2025 was HK$-51.8 Mil. 3D Medicines's Revenue for the six months ended in Dec. 2025 was HK$162.3 Mil. Therefore, 3D Medicines's Operating Margin % for the quarter that ended in Dec. 2025 was -31.91%.

The historical rank and industry rank for 3D Medicines's Operating Margin % or its related term are showing as below:

HKSE:01244' s Operating Margin % Range Over the Past 10 Years
Min: -834.86   Med: -56.64   Max: -17.82
Current: -20.81


HKSE:01244's Operating Margin % is ranked better than
62.78% of 943 companies
in the Biotechnology industry
Industry Median: -83.62 vs HKSE:01244: -20.81

3D Medicines's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

3D Medicines's Operating Income for the six months ended in Dec. 2025 was HK$-51.8 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-81.3 Mil.


3D Medicines  (HKSE:01244) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


3D Medicines Operating Margin % Related Terms


3D Medicines Operating Margin % Historical Data

* Premium members only.

The historical data trend for 3D Medicines's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

3D Medicines Operating Margin % Chart

3D Medicines Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial -834.86 -56.64 -66.37 -17.82 -20.76

3D Medicines Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only -106.38 -23.63 -12.80 -12.93 -31.91

HKSE:01244 vs VRTX, REGN, RVMD: Operating Margin % Comparison

For the Biotechnology subindustry, 3D Medicines's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


3D Medicines Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 3D Medicines's Operating Margin % distribution charts can be found below:

* The bar in red indicates where 3D Medicines's Operating Margin % falls into.


HKSE:01244
49GF Score
3D Medicines Inc HKSE:01244
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

3D Medicines Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

3D Medicines's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-81.663 / 393.379
=-20.76 %

3D Medicines's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=-51.794 / 162.307
=-31.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -31.91% mean?
3D Medicines (HKSE:01244) has a Operating Margin % of -31.91% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on 3D Medicines and its competitors. According to the industry distribution chart, 3D Medicines ranks #351 out of 943 companies in the Biotechnology industry, placing it in the top 37.2%.
Is 3D Medicines' Operating Margin % too high?
3D Medicines' current Operating Margin % is -31.91%. Based on the distribution chart, 3D Medicines ranks #351 out of 943 companies in the Biotechnology industry, which is above the industry midpoint. Overall, 3D Medicines has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does 3D Medicines' Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 3D Medicines ranks #351 out of 943 companies for Operating Margin %. This puts 3D Medicines in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on 3D Medicines and its competitors. 3D Medicines's current Operating Margin % is -31.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3D Medicines stock overvalued right now?
Based on GuruFocus' analysis, 3D Medicines (HKSE:01244) is currently considered Possible Value Trap. The stock's GF Value™ is HK$3.15, compared to a current price of HK$2.02 — trading 36% below its estimated fair value. The current Operating Margin % is -31.91%. 3D Medicines' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For 3D Medicines (HKSE:01244), the current Operating Margin % is -31.91% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 3D Medicines (HKSE:01244) Overvalued in 2026?

Based on GuruFocus' analysis, 3D Medicines stock appears to be undervalued. The current stock price of HK$2.02 is trading 36% below its estimated GF Value™ of HK$3.15. GuruFocus considers 3D Medicines to be Possible Value Trap.

Key valuation signals for HKSE:01244:

  • Operating Margin %: -31.91%
  • GF Value™: HK$3.15 vs. price of HK$2.02 (36% below fair value)
  • GF Score™: 49/100 with 5 warning signs

No single metric tells the full story. See the HKSE:01244 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


3D Medicines Business Description

Address No. 3 and No. 5, Laiyang Road, Shandong Province, Shinan District, Qingdao, CHN
3D Medicines Inc is an investment holding company. The company and its subsidiaries are principally engaged in the research, development and commercialisation of pharmaceutical products.It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life. It generates all of its revenue from China. Its commercialized product is Envita.
49GF Score

Get the complete analysis for HKSE:01244

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$2.02
Price
HK$3.15
GF Value